The study is examining the impact of molecular testing on breast cancer care and outcomes. Credit: CDC on Unsplash.

Veracyte has announced that new data from the EMIT trial indicates the use of the Prosigna Breast Cancer Assay significantly changed treatment decisions for individuals diagnosed with early-stage breast cancer.

The study’s data demonstrated that the assay has also minimised the utilisation of chemotherapy in patients with clinically high-risk diseases.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The prospective, multi-year, population-based EMIT study in Norway is examining the impact of molecular testing, particularly the Prosigna test, on breast cancer care and outcomes.

The research conducted assessed a group of 2,164 women in Norway diagnosed with early-stage (node-negative) breast cancer.

The objective was to analyse the treatment decisions made by physicians for these patients before and after obtaining the results of a Prosigna test.

The researchers noticed that using Prosigna led to a change in adjuvant therapy decisions for nearly one-third (29%) of patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Prosigna examines the PAM50 gene signature activity and clinical-pathological features to offer a hormone-receptor-positive early breast cancer patient and their physician a prognostic score.

This score indicates the likelihood of cancer returning within the next ten years if the patient undergoes endocrine therapy alone.

The test can be conducted using the nCounter Analysis System and is accessible to laboratories in Europe and other regions.

Veracyte breast cancer medical director Kelly Marcom said: “We are honoured that the Prosigna test was selected to be part of EMIT, which we believe is among the most rigorous studies to evaluate the impact of gene expression testing on clinical decision-making and patient outcomes in breast cancer.”